Asset Details
Do you wish to reserve the book?
A novel DNA vaccine encoding the SRS13 protein administered by electroporation confers protection against chronic toxoplasmosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A novel DNA vaccine encoding the SRS13 protein administered by electroporation confers protection against chronic toxoplasmosis
Do you wish to request the book?
A novel DNA vaccine encoding the SRS13 protein administered by electroporation confers protection against chronic toxoplasmosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A novel DNA vaccine encoding the SRS13 protein administered by electroporation confers protection against chronic toxoplasmosis
2024
Overview
Toxoplasma gondii is an obligate intracellular parasite that can infect a variety of mammals including humans and causes toxoplasmosis. Unfortunately, a protective and safe vaccine against toxoplasmosis hasn’t been developed yet. In this study, we developed a DNA vaccine encoding the SRS13 protein and immunized BALB/c mice thrice with pVAX1-SRS13 through the intramuscular route (IM) or intradermally using an electroporation device (ID + EP). The immunogenicity of pVAX1-SRS13 was analyzed by ELISA, Western blot, cytokine ELISA, and flow cytometry. The protective efficacy of the pVAX1-SRS13 was investigated by challenging mice orally with T. gondii PRU strain tissue cysts. The results revealed that pVAX1-SRS13 administered through IM or ID + EP routes induced high level of anti-SRS13 IgG antibody responses (P = 0.0037 and P < 0.0001). The IFN-γ level elicited by the pVAX1-SRS13 (ID + EP) was significantly higher compared to the control group (P = 0.00159). In mice administered with pVAX1-SRS13 (ID + EP), CD8+ cells secreting IFN-γ was significantly higher compared to pVAX1-SRS13 (IM) (P = 0.0035) and the control group (P = 0.0068). Mice vaccinated with the SRS13 DNA vaccine did not induce significant IL-4 level. Moreover, a significant reduction in the number of tissue cysts and the load of T. gondii DNA was detected in brains of mice administered with pVAX1-SRS13 through ID + EP and IM routes compared to controls. In conclusion, the SRS13 DNA vaccine was found to be highly immunogenic and confers strong protection against chronic toxoplasmosis.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Animals
/ Antibodies, Protozoan - blood
/ Antibodies, Protozoan - immunology
/ Antigens
/ Antigens, Protozoan - genetics
/ Antigens, Protozoan - immunology
/ CD8-Positive T-Lymphocytes - immunology
/ Cysts
/ DNA
/ E coli
/ Enzyme-linked immunosorbent assay
/ Enzymes
/ Female
/ Interferon-gamma - immunology
/ Mice
/ Proteins
/ Protozoa
/ Protozoan Proteins - genetics
/ Protozoan Proteins - immunology
/ Protozoan Vaccines - administration & dosage
/ Protozoan Vaccines - immunology
/ SRS13
/ Toxoplasmosis - prevention & control
/ Toxoplasmosis, Animal - immunology
/ Toxoplasmosis, Animal - prevention & control
/ Vaccines
